Evaluation lncRNA RBPMS-AS1 expression levels in thyroid cancer healthy tissues as a diagnostic and therapeutic target

Abstract

Papillary thyroid cancer (PTC), the most common endocrine malignancy, accounts for about 85% of all thyroid cancers. Surgery is considered the primary treatment for this disease. However, its global incidence is increasing rapidly. In recent years, studies have shown that inappropriate gene expression due to genomic instability or changes in epigenetic markers plays a major role in PTC regulation. With more than 200 nucleotides in length, LncRNAs are part of gene expression products that do not translate into proteins. The function of these molecules depends on their unique molecular structure, and thus they play an important role in modulating various oncogenes and suppressor genes. Many lncRNAs, such as RBPMS-AS1, have reportedly been out of order in various cancers. This lncRNA has been shown to play a significant role in the proliferation, migration, and EMT of cancers. Therefore, in this study, the expression of RBPMS-AS1 in tissue and bioinformatics samples was investigated to investigate its role in the initiation and progression of thyroid cancer. Matherial and method: First, 20 samples of thyroid cancer tissue and 20 samples of adjacent healthy tissue were taken from patients. RNA was then extracted from the samples and cDNA was synthesized. Then, using qPCR, the expression of RBPMS-AS1 in the samples was measured and its relationship with clinical and pathological features was investigated. Also, to confirm the results, gene expression was evaluated informatically using TCGA database data in cancer samples compared to healthy samples. Also, the diagnostic power of this marker was evaluated using ROC curve analysis and its relationship with patient survival by the Kaplan-Meier method. Resaults: The results showed that the expression level of RBPMS-AS1 was significantly reduced in cancer samples compared to healthy samples and these results were confirmed by TCGA database data. Further analysis of TCGA data also indicates a negative and significant relationship between RBPMS-AS1 expression and cancer stage and the survival rate of patients with end-stage thyroid disease. In addition, ROC curve analysis showed that the expression pattern of this gene could be considered a potential diagnostic biomarker for thyroid cancer.